SEC Form 4 · accession 0001209191-19-013531
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Bowden
Officer — Chief Medical Officer
Period of report
Feb 22, 2019
Accepted (ET)
Feb 26, 2019 · 4:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $58.86 | Feb 22, 2019 | A | 40,000 | A | — | Feb 22, 2029 | Common stock | 40,000 | 40,000 | D |
| Restricted stock unitsF2,F3 | — | Feb 22, 2019 | A | 10,000 | A | — | — | Common stock | 10,000 | 10,000 | D |
Explanation of responses
- F1This option was granted on February 22, 2019. The shares underlying this option vest as to 25% of the underlying shares on February 22, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- F2Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F3The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.